[Evolution of transfusionnal requirements in hematology].
Predicting transfusion requirements relies both on epidemiology and therapeutic changes in hematology. The incidence rate of B-cell neoplasias especially non-Hodgkin lymphoma and myelodysplasia is increasing. Chemotherapy related myelodysplasia will reflect the improvement of solid tumor prognostic in the future. For myelodysplasias, therapeutic changes including oral iron chelators and more intensive transfusion policies will likely result in an increase of PRC requirements, a situation shared by sickle-cell disease.
Renaudier
P
P
Unité d'hémovigilance, hôpital de la Croix-Rousse, Lyon, France. philippe.renaudier@chu-lyon.fr
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D000755:Anemia, Sickle Cell / Q000453:epidemiology / Q000628:therapy; D000970:Antineoplastic Agents / Q000009:adverse effects; D001803:Blood Transfusion / Q000592:standards / Q000639:trends*; D002614:Chelating Agents / Q000627:therapeutic use; D015913:Chelation Therapy / Q000706:statistics & numerical data; D002648:Child; D005260:Female; D005602:France / Q000453:epidemiology; D006301:Health Services Needs and Demand / Q000639:trends*; D006402:Hematologic Diseases / Q000453:epidemiology / Q000628:therapy*; D019337:Hematologic Neoplasms / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D007501:Iron; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000453:epidemiology / Q000628:therapy; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate
D000970:Antineoplastic Agents; D002614:Chelating Agents; D007501:Iron